51-102F3
MATERIAL CHANGE REPORT

Item 1 Name and Address of Company

Global UAV Technologies Inc. (the "**Company**")
#1212 – 1030 West Georgia Street
Vancouver, British Columbia, V6E 2Y3

Item 2 Date of Material Change

August 24, 2026

Item 3 News Release

The news release dated August 24, 2026 was disseminated through Newsfile Corp.

Item 4 Summary of Material Change

On August 24, 2026, the Company announced that it has entered into a definitive amalgamation agreement dated August 24, 2026 (the "**Amalgamation Agreement**") with Nexus Peptide Sciences Inc. ("**Nexus**"), a private corporation existing under the laws of British Columbia, and 1604759 B.C. Ltd. ("**Newco**") a private corporation existing under the laws of British Columbia, pursuant to which the Company would complete a business combination with Nexus and acquire all of the outstanding securities of Nexus from the securityholders of Nexus by way of "three-cornered" amalgamation (the "**Transaction**").

Item 5 Full Description of Material Change

On August 24, 2026, the Company entered into the Amalgamation Agreement with Nexus, pursuant to which the Company would acquire all of the outstanding securities of Nexus from the Nexus Shareholders.

About Nexus Peptide Sciences Inc.

Nexus Peptide Sciences Inc. is a private biotechnology company, based in Vancouver, British Columbia. Nexus is developing optimized peptide formulations and next-generation delivery systems intended to improve stability, absorption and practical use across metabolic health, recovery and longevity applications.

Peptides are short chains of amino acids that act as native signalling molecules, regulating metabolism, repair, immunity and cognition. Nexus' platform is directed at what the company identifies as the principal constraint on peptide adoption —the molecule itself and the route of delivery, as most peptides degrade rapidly, struggle to cross biological barriers and require injection to remain stable.

Nexus' work spans five areas: molecular optimization (sequence and structural refinement to improve stability, half-life and target selectivity); formulation chemistry (excipient and carrier systems engineered for solubility, shelf-stability and consistent dosing); researching optimal delivery systems (needle-free formats including transdermal patches, oral platforms and absorption-enhanced carriers); quality and verification (manufacturing in approved facilities with batch-level third-party analytical testing for identity, purity and contamination); and regulatory alignment (monitoring of U.S. and international policy to align product positioning with the evolving framework for peptide-based products).

Further information regarding Nexus, its business, its programs and its financial position will be included in the listing statement to be prepared in connection with the Transaction and filed under the Company's profile on SEDAR+.

Summary of the Transaction

Pursuant to the terms of the Amalgamation Agreement, the Company has agreed to acquire all of the issued and outstanding common shares (each, a "**Nexus Share**") of Nexus by way of "three-cornered" amalgamation whereby Newco and Nexus will amalgamate to form a new entity ("**Amalco**"), and Amalco will be a wholly-owned subsidiary of the Company upon completion of the Transaction (the "**Closing**"). At the effective time of the Closing, each of the outstanding Nexus Shares will be cancelled and, in consideration for such Nexus Shares, each respective Nexus shareholder will receive their pro rata portion of an aggregate of 20,500,000 common shares (each, a "**Share**") in the capital of the Company and 7,000,000 transferable share purchase warrants (each, a "**Warrant**") of the Company. Each Warrant is exercisable into one (1) additional Share (each, a "**Warrant Share**") at an exercise price of $0.10 per Warrant Share for a period of two (2) years following the Closing. The Company and Nexus negotiated at arm's length and no valuations were obtained.

Immediately prior to the Closing, the Company has agreed that there will be no more than 33,000,000 Shares and 17,000,000 share purchase warrants issued and outstanding, with such warrants to have an exercise price of $0.10 per Share. Following completion of the Transaction. The Company anticipates that there will be a finder's fee in connection with the Transaction comprised of $100,000 in cash and 1,000,000 in Shares.

The Transaction is considered a Fundamental Change pursuant to the policies of the Canadian Securities Exchange (the "**CSE**"), requiring the CSE to review and approve the Transaction. The Transaction is an arm's length transaction. The Transaction will be completed pursuant to available exemptions under applicable legislation.

Concurrent Financing

On or before the Closing of the Transaction, the Company intends on completing an equity financing of a minimum of $3,000,000 and a maximum of $5,000,000.

Board and Management

On Closing of the Transaction, the board of directors of the combined company (the "**Resulting Issuer**") will consist of five (5) directors — three (3) nominees of Nexus (Dr. Patrick Gunning, Dr. Mark Lindsay and Dr. Mona Ezzat-Velinov) and two (2) continuing directors of the Company (Ron Schmitz and Tim Ko). The Company anticipates that it on Closing Chris Cherry will be appointed as Chief Financial Officer. Additional information on the proposed directors, officers and Insiders (as defined in the policies of the CSE) of the Resulting Issuer will be included in subsequent press releases in connection with the Transaction.

Dr. Patrick Gunning — Proposed Director and Chief Scientific Officer

Dr. Gunning is a Professor of Molecular Therapeutics at the University of Glasgow and a Professor of Chemistry at the University of Toronto, and was previously a Canada Research

Chair in Medicinal Chemistry and founder and inaugural Director of the Centre for Medicinal Chemistry. He earned his Ph.D. from the University of Glasgow and completed postdoctoral studies at Yale University. He has authored over 140 research publications and is a Fellow of the Royal Society of Chemistry; his recognitions include the Boehringer Ingelheim Young Investigator Award, the RSC MedChemComm Emerging Investigator Lectureship and Canada's Top 40 Under 40. Dr. Gunning has co-founded multiple biotechnology companies, including Janpix Inc., Centessa Pharmaceuticals (Nasdaq: CNTA), Dunad Therapeutics, Dalriada Drug Discovery, HDAX Therapeutics and Carnyx Therapeutics.

Dr. Mark Lindsay — Proposed Director

Dr. Lindsay is a Doctor of Chiropractic and a graduate of Palmer Chiropractic College, with 35 years of experience working with elite athletes, including Super Bowl, Stanley Cup and MLB championship teams and Olympic and world champions. He is a Diplomate of the American Chiropractic Neurology Board and a member of the Ontario and Colorado Chiropractic Associations, and is a Ph.D. candidate in the Neuroscience Program at Queen's University. He has completed over 3,000 hours of graduate study in neurology through the Carrick Institute for Graduate Studies, is the author of Fascia: Clinical Applications for Health and Human Performance and ten research publications, and serves as a Research Fellow at the Steadman Philippon Research Institute in Vail, Colorado. He is a co-founder of Carnyx Therapeutics, Kelvin Therapeutics and Entourage AI.

Dr. Mona Ezzat-Velinov — Proposed Director

Dr. Ezzat-Velinov is a board-certified family physician with more than 25 years of clinical experience specializing in integrative and functional medicine, and works in longevity medicine. She has provided expertise to healthcare and technology organizations including Apple, Facebook, One Medical, Human Longevity and Fountain Life, is a frequent conference speaker including at the Buck Institute, and has authored published chapters on integrative wellness and women's longevity. She is a member of the American Academy of Family Physicians, the Institute for Functional Medicine and the Mast Cell Academy.

Chris Cherry — Proposed Chief Financial Officer

Mr. Cherry has over 20 years of corporate accounting and audit experience and has held senior positions with several public mining companies, including director, chief financial officer and secretary. He is a CPA, having obtained the Chartered Accountant designation in 2009 and the Certified General Accountant designation in 2004. He previously held positions with KPMG and Davidson & Co. LLP in Vancouver, auditing junior public companies.

Ron Schmitz — Continuing Director, President and Chief Executive Officer

Mr. Schmitz has been a director, chief executive officer and chief financial officer of numerous public companies since 1997, and is an active participant in the junior markets. Mr. Schmitz is also the president of ASI Accounting Services Inc., which has provided administrative, accounting and office services to public and private companies since 1995.

Tim Ko — Continuing Director

Mr. Ko is an entrepreneur who has successfully founded and operated businesses in technology and biotech. He has served at both the executive and board level, and has overseen the successful financing, acquisition and operations of businesses in his time within the Canadian public markets.

Completion of the Transaction remains subject to a number of conditions, including satisfactory due diligence, entry into the Definitive Agreement, completion of audited financial statements for Nexus, the receipt of all requisite approvals required to consummate the Transaction, and other conditions customary for transactions of this nature. The LOI includes a completion deadline of August 31, 2026. The parties will endeavor to complete the Transaction as soon as practicable and intends to complete the Transaction prior to the completion deadline. There can be no assurance that the Transaction will be completed as proposed or at all.

Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

N/A

Item 7 Omitted Information

None

Item 8 Executive Officer

Ron Schmitz, CEO, (604) 685-7450

Item 9 Date of Report

August 24, 2026